Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients

Table 1 Characteristics of included studies and schedules of antiviral treatment

Ref.	Number of patients, n (total/SO + IFN1)	Country	Study design	Spleen operation	Antiviral agents	Doses of IFN and RBV	Therapy duration
Aizawa et al[17], 2013	90/30	Japan	Retrospective, controlled	Splenectomy (2 PSE)	PegIFN-α-2a or PegIFN-α-2b + RBV	PegIFN-α-2a: 180 ug/wk; PegIFN-α-2b: 1.0-1.5 μg/kg per week; RBV: 600-1000 mg/d	GT 1: at least 48 wk;
							GT 2/3: at least 24 wk
Akahoshi et al[18], 2012	100/97	Japan	Retrospective, cohort	Splenectomy	PegIFN-α-2b + RBV	PegIFN-α-2b: 1.5 μg/kg per week; RBV: 600-1000 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Hayashi et al[11], 2006	6/6	United States	Retrospective, cohort	Splenectomy	PegIFN-α-2b + RBV	PegIFN-α-2b: 1.5 μg/kg per week; RBV: 600-1000 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Ikezawa et al[19], 2010	10/10	Japan	Retrospective, cohort	Splenectomy	PegIFN-α-2a or PegIFN-α-2b + RBV	PegIFN-α-2a: 180 ug/wk; PegIFN-α-2b: 1.5 μg/kg per week; RBV: 600-1000 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Ji et al[20], 2013	13/13	China	Prospective, cohort	Splenectomy	PegIFN-α-2a (2) or PegIFN-α-2b (3) or IFN-α-2b (8) + RBV	PegIFN-α-2a: 180 ug/wk; PegIFN-α-2b: 1.5 μg/kg per week; IFN-α-2b: 2.1-3.0 MU, tiw; RBV: 800-1000 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Kedia et al[21], 2012	6/6	Japan	Retrospective, cohort	Splenectomy	PegIFN (2) or IFN (4) + RBV	NA	NA
Kercher et al[22], 2004	11/11	United States	Prospective, cohort	Splenectomy	PegIFN + RBV	NA	NA
Liang et al[23], 2008	9/9	China	Retrospective, cohort	Splenectomy	PegIFN-α-2a (6) or IFN-α-2b (3) + RBV	PegIFN-α-2a: 180 ug/wk; IFN-α-2b: 5MU tiw; RBV: 900-1200 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Morihara et al[24], 2009	48/16	Japan	Retrospective, controlled	Splenectomy	PegIFN-α-2b (2) or IFN-α (14) + RBV	PegIFN-α-2b: 50 μg/wk; IFN-α: 3.0-6.0 MU, tiw; RBV: 400 mg/d	1.4 yr (range: 0.2-12.4 yr)
Motomura et al[25], 2012	127/37	Japan	Retrospective, controlled	Splenectomy	PegIFN + RBV	NA	NA
Shigekawa et al[26], 2011	29/292	Japan	Retrospective, cohort	Splenectomy	PegIFN-α-2a or PegIFN-α-2b + RBV	PegIFN-α-2a: 90 μg/wk; or PegIFN-α-2b: 0.75 μg/kg per week; RBV: 800 mg/d	GT 1: 48 wk;
							GT 2/3: 24 wk
Xie et al[27], 2012	49/49	China	Retrospective, controlled	Splenectomy PSE	PegIFN-α-2a + RBV	PegIFN-α-2a: 135 or 180 μg/wk; RBV: 800-1200 mg/d	NA
Foruny et al[28], 2005	8/8	Spain	Retrospective, cohort	PSE	PegIFN-α-2a (2) or PegIFN-α-2b (6) + RBV	PegIFN-α-2a: 180 ug/wk; PegIFN-α-2b: NA; RBV: 8.8-18.18 mg/kg per day	24-48 wk
Miyake et al[29], 2008	20/10	Japan	Case controlled	PSE	PegIFN-α-2b (5) or IFN-α-2b (5) + RBV	PegIFN-α-2b: 1.2 μg/kg per week; IFN-α-2b: 6MU tiw; RBV: 400 - 800 mg/d	24-48 wk
Tahara et al[30], 2011	53/30	Japan	Case controlled	PSE	PegIFN-α-2a (2) or PegIFN-α-2b (2) + RBV	NA	24-48 wk
Takahara et al[31], 2011	24/11	Japan	Case controlled	PSE	PegIFN-α-2b + RBV	PegIFN-α-2b: 1.2 μg/kg per week;	GT 1: 48 wk;
						RBV: 400-800 mg/d	GT 2/3: 24 wk
Summary	603/372

¹Total: All patients received IFN and RBV treatment; SO + IFN: Patients treated with spleen operation before IFN and RBV treatment;

²Among 35 patients enrolled in this study, six did not receive antiviral therapy because of HCC (2), cerebral infarction (2), colonic perforation (1) or other cancer (1). SO: Spleen operation; IFN: Interferon; RBV: Ribavirin; GT: Genotype; PSE: Partial splenic embolization; NA: Not available.